Alumis set for worst day after lupus drug misses main goal in mid-stage trial
ALMS•Subgroup response and next steps
Alumis said a prespecified subgroup of patients with a high interferon gene signature, a marker linked to inflammation in lupus, showed responses on the main efficacy measure and key secondary endpoints.
The company plans to discuss late-stage development with regulators based on those subgroup results.
Alumis said envudeucitinib was generally well-tolerated and no new safety signals were observed.
The company remains on track to file for U.S. approval of envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026.
Including the session's move, the stock was up about 9% year to date.
Shares fall after mid-stage lupus trial misses endpoints
Shares of biopharma company Alumis ALMS.O fell 54.2% to $9.99, their lowest since January.
The stock was on track for its worst day on record if losses hold.
The company said its mid-stage study of experimental drug envudeucitinib in systemic lupus erythematosus, an autoimmune disease in which the immune system attacks healthy tissues, missed both primary and secondary goals in the overall patient group.
